Development of S-PCT3010 to treat cognitive impairment in Alzheimers Disease

Polycore Treateutics LLC正在开发S-PCT3010作为改善认知能力的治疗药物 帕金森病患者的功能状况及对S-PCT3010的评估 作为改善阿尔茨海默病患者认知功能的一种治疗方法。S-PCT3010是一个 选择性D3R激动剂，有偏见的信号通过G蛋白途径传递，而不是 招募-arrestin。该药物不会在体外或体内诱导大鼠耐受。此外，S-- PCT3010是一种去甲肾上腺素转运体的选择性抑制剂，并促进 帕金森氏病啮齿动物模型的持续注意力和认知灵活性 产生强迫或冲动行为的。S-PCT3010具有高度的药效学易控性 具有极好的口服生物利用度和血脑屏障穿透性。在本提案中，Polycore Treateutics LLC计划完成体内转基因小鼠模型的初步研究 应用S-PCT3010评估阿尔茨海默病患者的行为和病理改变 行政管理。 根据阿尔茨海默氏症协会的数据，估计有580万65岁及以上的美国人 2020年，80%的人患有阿尔茨海默氏症，年龄在75岁以上。这些 数字代表十分之一的65岁以上的人生活在不同的认知能力 减损。阿尔茨海默氏症也是一种重大的死亡风险，是第六大 是美国最大的死因。阿尔茨海默病的经济负担是 预计2020年的成本将超过1.1万亿美元，其中很大一部分成本 与认知障碍和痴呆症相关的患者管理。在此应用程序中， Polycore Treateutics LLC与领先的帕金森和阿尔茨海默氏症研究人员在 德雷克塞尔大学评估阿尔茨海默氏症导致的认知功能变化 疾病。该团队计划评估S-PCT3010在缓解认知障碍方面的使用 以及使用阿尔茨海默病转基因小鼠模型的记忆丧失。多核 Treateutics LLC正在积极开发治疗帕金森病的S-PCT3010 第二阶段SBIR(1R44NS117201-01)。

PolyCore Therapeutics LLC is developing S-PCT3010 as a therapeutic for improved cognitive function in patients suffering from Parkinson’s Disease and is proposing to evaluate S-PCT3010 as a therapeutic for improved cognitive function in Alzheimer’s patients. S-PCT3010 is a selective D3R agonist with biased signaling through the G-protein pathway which does not recruit -arrestin. The drug does not induce tolerance in vitro or in vivo in rats. Further, S- PCT3010 is a selective inhibitor of norepinephrine transporter and promotes improvement in sustaining attention and cognitive flexibility in rodent models of Parkinson’s Disease without producing compulsive or impulsive behaviors. S-PCT3010 is highly pharmaceutically tractable with excellent oral bioavailability and blood brain barrier penetration. In this proposal, PolyCore Therapeutics LLC is proposing to complete pilot studies in a in vivo transgenic mouse model of Alzheimer’s Disease evaluating both behavioral and pathological changes following S-PCT3010 administration. Per the Alzheimer’s Association, an estimated 5.8 million Americans age 65 and older are living with Alzheimer's dementia in 2020 with eighty percent over 75 years old. These numbers represent one in ten people over the age of 65 living with various cognitive impairments. Alzheimer's Disease also represents a significant risk of death and is the sixth- leading cause of death in the United States. The financial burden of Alzheimer's Disease is projected to cost more than $1.1 trillion dollars in 2020, and a significant portion of this cost relates to patient management around cognitive disorders and dementia. In this application, PolyCore Therapeutics LLC teams with leading Parkinson’s and Alzheimer’s researchers at Drexel University to evaluate the changes in cognitive function resulting from Alzheimer’s Disease. The team plans to evaluate S-PCT3010 for use in mitigation of cognitive disorders and memory loss using a transgenic mouse model of Alzheimer’s disease. PolyCore Therapeutics LLC is actively developing S-PCT3010 for Parkinson Disease under an ongoing Phase II SBIR (1R44NS117201-01).